Nobuhiro Nakazawa

Dr. Nobuhiro Nakazawa

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2019 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NNNobuhiro Nakazawa
Nobuhiro Nakazawa
Takehiko YokoboriTakehiko Yokobori
Takehiko Yokobori
KKKyoichi Kaira
Kyoichi Kaira
ATAndrei Turtoi
Andrei Turtoi
SBSeded Baatar
Seded Baatar
KSKen Shirabe
Ken Shirabe

28 July 2024 in Cancers
Verified
Journal Article
Open access
PDF file
NMNatsumi Mori
Natsumi Mori
GDGendensuren Dorjkhorloo
Gendensuren Dorjkhorloo
TSTakuya Shiraishi
Takuya Shiraishi
BOBilguun Erkhem Ochir
Bilguun Erkhem Ochir
HOHaruka Okami
Haruka Okami
HSHiroshi Saeki
Hiroshi Saeki
Tertiary lymphoid structures (TLSs) are complex lymphocyte clusters that arise in non-lymphoid tissues due to inflammation or cancer. A mature TLS with proliferating germinal centers is associated with a favorable prognosis in various cancers. However, the effect of TLS maturity on advanced colorectal cancer (CRC) remains unexplored. We analyzed the significance of TLS maturity and tumor Ki-67 expression in surgically resected tumors from 78 patients with pathological T4 CRC. Mature TLS was defined as the organized infiltration of T and B cells with Ki-67-positive proliferating germinal centers. We analyzed the relationship between TLS maturity and intratumoral immune cell infiltration. Mature TLS with germinal center Ki-67 expression was associated with microsatellite instability and improved survival; however, high tumor Ki-67 expression was associated with poor survival in the same cohort. Multivariate analysis identified the absence of mature TLS as an independent predictor of poor post-recurrence overall survival. Intratumoral infiltration of T lymphocytes and macrophages was significantly elevated in tumors with mature TLS compared to those lacking it. High Ki-67 levels and absent mature TLS were identified as poor prognostic factors in advanced CRC. Mature TLS could serve as a promising marker for patients at high-risk of CRC.

3 September 2024 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
NNNobuhiro Nakazawa
Nobuhiro Nakazawa
MSMakoto Sohda
Makoto Sohda
NHNobuhiro Hosoi
Nobuhiro Hosoi
TWTakayoshi Watanabe
Takayoshi Watanabe
YKYuji Kumakura
Yuji Kumakura
HSHiroshi Saeki
Hiroshi Saeki

Verified
Journal Article
Open access
PDF file
NNNobuhiro Nakazawa
Nobuhiro Nakazawa
Takehiko YokoboriTakehiko Yokobori
Takehiko Yokobori
MSMakoto Sohda
Makoto Sohda
NHNobuhiro Hosoi
Nobuhiro Hosoi
TWTakayoshi Watanabe
Takayoshi Watanabe
HSHiroshi Saeki
Hiroshi Saeki
Lipopolysaccharides are a type of polysaccharide mainly present in the bacterial outer membrane of Gram-negative bacteria. Recent studies have revealed that lipopolysaccharides contribute to the immune response of the host by functioning as a cancer antigen. We retrospectively recruited 198 patients with gastric cancer who underwent surgery. The presence of lipopolysaccharides was determined using immunohistochemical staining, with the intensity score indicating positivity. The relationship between lipopolysaccharides and CD8, PD-L1, TGFBI (a representative downstream gene of TGF-β signaling), wnt3a, and E-cadherin (epithelial–mesenchymal transition marker) was also investigated. Thereafter, we identified 20 patients with advanced gastric cancer receiving nivolumab and investigated the relationship between lipopolysaccharides and nivolumab sensitivity. After staining for lipopolysaccharides in the nucleus of cancer cells, 150 negative (75.8%) and 48 positive cases (24.2%) were found. The lipopolysaccharide-positive group showed increased cancer stromal TGFBI expression (p < 0.0001) and PD-L1 expression in cancer cells (p = 0.0029). Lipopolysaccharide positivity was significantly correlated with increased wnt3a signaling (p = 0.0028) and decreased E-cadherin expression (p = 0.0055); however, no significant correlation was found between lipopolysaccharide expression and overall survival rate (p = 0.71). In contrast, high TGFBI expression in the presence of LPS was associated with a worse prognosis than that in the absence of LPS (p = 0.049). Among cases receiving nivolumab, the lipopolysaccharide-negative and -positive groups had disease control rates of 66.7% and 11.8%, respectively (p = 0.088). Lipopolysaccharide positivity was associated with wnt3a, TGF-β signaling, and epithelial–mesenchymal transition and was considered to tend to promote therapeutic resistance to nivolumab.

31 July 2019 in Anticancer Research
Verified
Journal Article
Closed access
NNNobuhiro Nakazawa
Nobuhiro Nakazawa
KOKyoichi Ogata
Kyoichi Ogata
Takehiko YokoboriTakehiko Yokobori
Takehiko Yokobori
MIMunenori Ide
Munenori Ide
SBSeded Baatar
Seded Baatar
KSKen Shirabe
Ken Shirabe
We investigated whether the expression of inositol 1, 4, 5-trisphosphate receptor-binding protein released with inositol 1, 4, 5-trisphosphate (IRBIT) in clinical gastric cancer (GC) patients could predict the therapeutic response to postoperative adjuvant chemotherapy. Immunohistochemistry was used to investigate IRBIT expression in 115 GC patients. To clarify whether IRBIT had a relationship with the therapeutic effects of chemotherapy, we compared two groups - 62 patients treated with postoperative adjuvant chemotherapy and 53 patients treated with postoperative adjuvant chemotherapy. Regarding the postoperative adjuvant chemotherapy-free group, we did not find any statistically significant correlation between clinicopathological features and recurrence regardless of the expression of IRBIT. In contrast, in the group receiving postoperative adjuvant chemotherapy, a significant association was found between IRBIT expression and both overall and disease-free survival. IRBIT may be used as a useful predictive marker for chemotherapy.

Verified
Journal Article
Open access
PDF file
YSYuta Shibasaki
Yuta Shibasaki
Takehiko YokoboriTakehiko Yokobori
Takehiko Yokobori
MSMakoto Sohda
Makoto Sohda
ISIkuma Shioi
Ikuma Shioi
NONaoya Ozawa
Naoya Ozawa
HSHiroshi Saeki
Hiroshi Saeki
The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.